Home/Pipeline/TRV734

TRV734

Opioid Use Disorder

Phase 1Active

Key Facts

Indication

Opioid Use Disorder

Phase

Phase 1

Status

Active

Company

Trevena

About Trevena

Trevena's mission is to develop safer and more effective CNS therapies by exploiting biased ligand signaling at G protein-coupled receptors (GPCRs). Its primary achievement is the 2020 FDA approval of OLINVYK, a biased mu-opioid receptor agonist for acute pain, though commercial uptake has been limited. The company's current strategy is to advance its early-stage pipeline, including TRV045 for neuropathic pain and epilepsy, while navigating severe financial constraints and seeking strategic alternatives to sustain operations.

View full company profile

Therapeutic Areas

Pain Migraine Opioid Use Disorder Neuropathic Pain Epilepsy Central Nervous System Disorders

Other Opioid Use Disorder Drugs

Drug	Company	Phase	Status
FP-004 (SIF Formulation)	Foresee Pharmaceuticals	Preclinical	Active
Vaxine Opioid Addiction Vaccine	Vaxine	Preclinical	Active
Safer Ibogaine Analogs	Gilgamesh Pharmaceuticals	Pre-clinical/Research	Active (NIDA Grant Funded)
AM-510	Aion Medicines	Discovery	Active
Naltrexone Implant	Delpor	Phase 1	Active
Platform Expansion	Amygdala Neurosciences	Research	Active
Undisclosed OUD Program	Epiodyne	Pre-clinical	Active
AQL™-Naltrexone	Plumb Pharmaceuticals	Pre-clinical	Active
MEB-1170	Mebias Discovery	Phase 1	Active
SUBLOCADE®	Indivior PLC	Marketed	Commercial